Results 181 to 190 of about 631,529 (311)

Delayed pharyngocutaneous fistula caused by molecular targeted therapy: a case report. [PDF]

J Med Case Rep, 2022
Matsuo M, Hashimoto K, Jiromaru R, Nakagawa T.   +3 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Research progress in molecular targeted therapy for inflammatory bowel disease. [PDF]

J Transl Med
Liu N, Pan C, Qu L.
europepmc   +1 more source

The advanced development of molecular targeted therapy for hepatocellular carcinoma. [PDF]

Cancer Biol Med, 2022
Yan T, Yu L, Zhang N, Peng C, Su G, Jing Y, Zhang L, Wu T, Cheng J, Guo Q, Shi X, Lu Y.   +11 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Molecular Targeted Therapy for Chronic Non-Bacterial Mastitis: New Insights into Pathophysiology and Therapeutic Strategies. [PDF]

Int J Womens Health
Xuan Z, Zheng K, Zhang D, Wei H.
europepmc   +1 more source

Multifunctional Nanoplatform Based on Sunitinib for Synergistic Phototherapy and Molecular Targeted Therapy of Hepatocellular Carcinoma. [PDF]

Micromachines (Basel), 2023
Xu W, Yang M, Du X, Peng H, Yang Y, Wang J, Zhang Y.   +6 more
europepmc   +1 more source

Molecular targeted therapy for renal cell carcinoma

, 2008
Renal cell carcinoma (RCC) accounts for approximately 2% of all cancer cases worldwide. Metastatic disease is often present at the time of diagnosis of RCC and its poor response to chemotherapy and radiotherapy causes poor prognosis.
吉田, 純, 中西, 弘之, 三木, 恒治, 水谷, 陽一, 水野, 正明   +4 more
core  

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

Molecular-targeted therapy in ameloblastoma: a systematic review. [PDF]

Arch Craniofac Surg
Sulistyani LD, Julia V, Ariawan D, Latief MA, Utomo YA, Aboy, Ghaisani A, Fadhliana D, Mas'ud NW.   +8 more
europepmc   +1 more source